Consistent with our stimulation study, the capacity of SHH to modulate proliferation of GSC resulted in an approx. twofold increase of [I-125]ITdU uptake in CD133+ cells (4.9%±0.6% vs. 2.5%±0.6% in CD133+ and CD133− glioma cells, respectively). The gene discussed is SHH; the disease is central nervous system cancer.